Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juniperus osteosperma pollen is a biological allergen extract derived from the Utah Juniper tree, a significant source of seasonal respiratory allergies in the Western United States. It is clinically utilized for both the diagnosis of IgE-mediated hypersensitivity and for allergen-specific immunotherapy (ASIT). In diagnostic applications, such as skin prick or intradermal testing, the extract cross-links allergen-specific IgE on the surface of mast cells and basophils, triggering the release of histamine and other inflammatory mediators that result in a localized wheal-and-flare reaction. For therapeutic purposes, the extract is administered in escalating doses to induce immunological tolerance. This process involves modulating the immune system to shift from a pro-inflammatory Th2 cytokine profile to a Th1-mediated response, expanding regulatory T cell (Treg) populations, and stimulating the production of allergen-specific IgG4 blocking antibodies that compete with IgE for allergen binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on juniperus osteosperma pollen.